NCT00186290

Brief Summary

To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
145

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 1989

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 1989

Completed
15.8 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 16, 2005

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2009

Completed
Last Updated

October 11, 2010

Status Verified

October 1, 2010

Enrollment Period

19.8 years

First QC Date

September 13, 2005

Last Update Submit

October 7, 2010

Conditions

Lymphoma, Non-HodgkinLeukemiaBlood and Marrow Transplant (BMT)Lymphomas: Non-Hodgkin

Outcome Measures

Primary Outcomes (2)

  • overall survival

    october 2009

  • disease free survival

    October 2009

Secondary Outcomes (1)

  • early and late toxicities of the treatment regimen

    October 2009

Interventions

ablative allogeneic hematopoietic cell transplantationPROCEDURE

Eligibility Criteria

AgeUp to 50 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • adequate organ function
  • other life threatening disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University School of Medicine

Stanford, California, 94305, United States

Location

MeSH Terms

Conditions

Lymphoma, Non-HodgkinLeukemia

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesHematologic Diseases

Study Officials

  • Robert Lowsky

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 16, 2005

Study Start

December 1, 1989

Primary Completion

October 1, 2009

Study Completion

October 1, 2009

Last Updated

October 11, 2010

Record last verified: 2010-10

Locations

US(1)